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Reply to the Editor:
Thank you for the invitation to respond to
Dr Casati and colleagues’ letter. We used
an in vitro bleeding time test (Platelet
Function Analyzer [PFA]-100) to evaluate
platelet function perioperatively at 7 differ-
ent observation times. Only one of these
observations was performed during cardio-
pulmonary bypass with hemodiluted pa-
tients. Fibrinolytic activity can indirectly
be measured, evaluating the balance be-
tween the promoter of fibrinolysis (tissue-
type plasminogen activator) and its inhibi-
tor (plasminogen activator inhibitor 1). In
our study1 we observed that tissue-type
plasminogen activator levels are not in-
creased, whereas plasminogen activator in-
hibitor 1 and D-dimer levels are modestly
increased after off-pump coronary artery
bypass (OPCAB) surgery. These data
would suggest that fibrinolysis is not par-
ticularly activated during OPCAB surgery.
Dr Casati states that an antifibrinolytic
agent should be used in patients undergo-
ing OPCAB surgery because he has previ-
ously demonstrated2 a significant reduction
of postoperative bleeding in patients under-
going OPCAB treated with tranexamic acid
(25 patients) compared with patients under-
going OPCAB treated with placebo (25
patients). In their study Casati and col-
leagues2 were not able to show a significant
difference in blood product transfusion be-
tween the groups. Moreover, hemoglobin
and hematocrit values reported up to 24
hours postoperatively were not influenced
by tranexamic acid administration. As we
remarked in our article, recent studies with
angiographic control have shown a worse
graft patency in patients operated on by
means of the OPCAB technique compared
with those undergoing the on-pump tech-
nique. Inaccurate anastomosis rather than a
procoagulative state is probably the main
cause of these results; nevertheless, this has
not been proved. Although numerous in-
vestigators have documented profound
short-term and midterm coagulative-
fibrinolytic and inflammatory alterations in
patients undergoing coronary artery bypass
grafting surgery, there are no clinical stud-
ies that evaluated prospectively and on an
appropriate number of patients the value of
prothrombotic and proinflammatory mark-
ers in predicting early graft occlusion. Ex-
isting studies are small and produced con-
flicting results: Poston and associates3
reported that thrombelastography and
whole blood aggregometry do not predict
graft occlusion; however, in another study
the same authors showed a reduction in
platelet sensitivity to aspirin by means of
both thrombelastography and aggregom-
etry in patients with early graft failure.4
Karski and coworkers5 have recently dem-
onstrated that tranexamic acid administra-
tion does not worsen early saphenous graft
patency in patients receiving on-pump cor-
onary artery bypass grafting. However, our
results show that in the first 24 hours after
the operation, patients undergoing on-
pump operations and OPCAB have a dif-
ferent activation of the coagulation and fi-
brinolytic systems. Consequently, what is
safe for patients undergoing on-pump op-
erations might not be safe for those under-
going OPCAB. The reason why we operate
on patients with coronary artery disease is
to improve their long-term outcome while
trying to minimize their perioperative risk.
Considering that postoperative bleeding is
not a serious complication after OPCAB
surgery, we agree with Dr Casati’s final
remarks: “Further randomized studies, en-
rolling larger numbers of patients, are
needed to confirm the antiinflammatory ef-
fects of TA and to rule out the potential risk
of thrombotic complications.”2
Domenico Paparella, MD
Antonella Galeone, MD
Giuseppe Scrascia, MD
Division of Cardiac Surgery
University of Bari
Piazza Giulio Cesare 11
Bari 70100
Italy
E-mail: paparella@tin.it
References
1. Paparella D, Galeone A, Venneri MT, Cov-
iello M, Scrascia G, Marraudino N, et al.
Activation of the coagulation system during
coronary artery bypass grafting operation:
comparison between on pump and off pump
techniques. J Thorac Cardiovasc Surg. 2006;
131:290-7.
2. Casati V, Della Valle P, Benussi S, Franco A,
Gerli C, Baili P, et al. Effects of tranexamic
acid on postoperative bleeding and related
hematochemical variables in coronary sur-
gery: comparison between on-pump and off-
pump techniques. J Thorac Cardiovasc Surg.
2004;128:83-91.
3. Poston R, Gu J, Brown J, Gammie J, White
C, Manchio J, et al. Hypercoagulability af-
fecting early vein graft patency does not exist
after off-pump coronary artery bypass. J Car-
diothorac Vasc Anesth. 2005;19:11-8.
4. Poston R, Gu J, Manchio J, Lee A, Brown
J, Gammie J, et al. Platelet function tests
predict bleeding and thrombotic events af-
ter off-pump coronary bypass grafting.
Platelet function tests predict bleeding and
thrombotic events after off-pump coronary
bypass grafting. Eur J Cardiothorac Surg.
2005;27:584-91.
5. Karski J, Djaiani G, Carroll J, Iwanochko M,
Seneviratne P, Liu P, et al. Tranexamic acid
and early saphenous vein graft patency in
conventional coronary artery bypass graft
surgery: a prospective randomized controlled
clinical trial. J Thorac Cardiovasc Surg.
2005;130:309-14.
doi:10.1016/j.jtcvs.2006.05.043
A new surgical paradigm: Hybrid
open and endovascular repair of the
ascending aorta and aortic arch for
acute type A dissection
To the Editor:
I read with interest the editorial by
Dobrilovic and Elefteriades1 reflecting on
the potential future application of simulta-
neous hybrid endoluminal graft repair of
the descending thoracic aorta after tradi-
tional open surgical repair of the ascending
aorta and aortic arch for acute type A aortic
dissection, as discussed in the article by
Uchida and associates.2
Although the results reported by Uchida
and associates2 are noteworthy, stabilizing
the true lumen in the descending thoracic
aorta with an endoluminal graft after total
aortic arch replacement may not be the final,
or best, approach for acute type A aortic
dissection. The current surgical paradigm is
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